İLKER ŞENGÜL
(İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, İzmir, Türkiye)
Şeniz AKÇAY YALBUZDAĞ
(İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, İzmir, Türkiye)
Buğra İNCE
(İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, İzmir, Türkiye)
ALTINAY GÖKSEL KARATEPE
(İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, İzmir, Türkiye)
Taciser KAYA
(İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, İzmir, Türkiye)
Yıl: 2016Cilt: 31Sayı: 2ISSN: 2148-5046 / 2618-6500Sayfa Aralığı: 127 - 132İngilizce

148 5
Are We Able to Suppress Disease Activity Adequately in Patients With Established Rheumatoid Arthritis? An Observational and Cross-Sectional Study
Fen > Tıp > Romatoloji
DergiAraştırma MakalesiErişime Açık
  • Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
  • Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
  • Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford) 2007;46:975-9.
  • Bal A, Ataman ?, Bodur H, Rezvani A, Paker N, Ta?tekin N, et al. Characteristics of patients with rheumatoid arthritis in Turkey: results from the Turkish Against Rheumatism Rheumatoid Arthritis Registry. Arch Rheumatol 2015;30:16-22.
  • Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57.
  • Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011;63:3702-11.
  • Gärtner M, Mandl P, Radner H, Supp G, Machold KP, Aletaha D, et al. Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. Arthritis Rheum 2013;65:2005-14.
  • Littlejohn G, Roberts L, Arnold M, Bird P, Burnet S, de Jager J, et al. A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control. Int J Rheum Dis 2013;16:532-8.
  • Tymms K, Zochling J, Scott J, Bird P, Burnet S, de Jager J, et al. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. Arthritis Care Res (Hoboken) 2014;66:190-6.
  • Horton SC, Walsh CA, Emery P. Established
  • rheumatoid arthritis: rationale for best practice: physicians' perspective of how to realise tight control in clinical practice. Best Pract Res Clin Rheumatol 2011;25:509-21.
  • Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
  • Fleischmann R, van der Heijde D, Koenig AS,
  • Pedersen R, Szumski A, Marshall L, et al. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? Ann Rheum Dis 2015;74:1132-7.
  • Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
  • Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Autoimmun Rev 2014;13:1102-8.
  • Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009;68:1094-9.
  • Listing J, Strangfeld A, Rau R, Kekow J, Gromnica- Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:66.
  • Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.